Dako/Genentech to submit HercepTest and HER2 FISH pharmDx as companion for T-DM1

Dako has signed an agreement with Genentech, member of the Roche Group, to collaborate on the regulatory submissions of Dako's HercepTest and HER2 FISH pharmDx as companion diagnostics for a Genentech investigational drug candidate, trastuzumab emtansine (T-DM1), in patients with advanced HER2-positive breast cancer. Under the terms of the agreement, Dako and Genentech will work together on the regulatory FDA submissions of HercepTest and HER2 FISH pharmDx to identify cancer patients who may be eligible for treatment with trastuzumab emtansine.

The collaboration is in line with Dako's ongoing strategy to combine its strengths with pharmaceutical companies to grow the offering of its companion diagnostic assays. The agreement comes on the heels of another collaboration between Dako and Genentech on the regulatory submissions of Dako's HercepTest and HER2 FISH pharmDx as companion diagnostics for another Genentech investigational drug candidate, pertuzumab.

Dako/Genentech to submit HercepTest and HER2 FISH pharmDx as companion for T-DM1

Dako has signed an agreement with Genentech, member of the Roche Group, to collaborate on the regulatory submissions of Dako's HercepTest and HER2 FISH pharmDx as companion diagnostics for a Genentech investigational drug candidate, trastuzumab emtansine (T-DM1), in patients with advanced HER2-positive breast cancer. Under the terms of the agreement, Dako and Genentech will work together on the regulatory FDA submissions of HercepTest and HER2 FISH pharmDx to identify cancer patients who may be eligible for treatment with trastuzumab emtansine.

The collaboration is in line with Dako's ongoing strategy to combine its strengths with pharmaceutical companies to grow the offering of its companion diagnostic assays. The agreement comes on the heels of another collaboration between Dako and Genentech on the regulatory submissions of Dako's HercepTest and HER2 FISH pharmDx as companion diagnostics for another Genentech investigational drug candidate, pertuzumab.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.